Radiologisches Monitoring bei Immuntherapie des Nierenzellkarzinoms

Zusammenfassung

In der Radiologie stellen die Response Evaluation Criteria in Solid Tumors (RECIST 1.1) die aktuell am weitesten etablierten Bewertungskriterien für das standardisierte Therapiemonitoring bei soliden Tumoren von klassischen zytostatischen und zytotoxischen Tumortherapien dar. Der zunehmende Einsatz von Immuncheckpointinhibitoren in der Therapie des metastasierten Nierenzellkarzinoms stellt das radiologische Therapiemonitoring durch das Auftreten atypischer Ansprechmuster und immuntherapiespezifischer Nebenwirkungen vor besondere Herausforderungen. Hier können angepasste Kriterien, wie beispielsweise immune RECIST (iRECIST), bei der Verlaufsbeurteilung des Nierenzellkarzinoms helfen, sowohl innerhalb als auch außerhalb klinischer Studien atypische Verläufe unter Immuncheckpointinhibitortherapie zu erfassen.

Abstract

The Response Evaluation Criteria in Solid Tumours (RECIST 1.1) currently represent the most widely established evaluation criteria for standardised therapy monitoring in solid tumours treated with traditional cytostatic and cytotoxic tumour therapies. The increasing use of immune checkpoint inhibitors in the therapy of metastatic renal cell carcinoma poses special challenges for radiological therapy monitoring due to the presence of atypical response patterns and immunotherapy-specific side-effects. Adapted criteria such as immune RECIST (iRECIST) can help in the follow-up assessment of renal cell carcinoma to detect atypical courses of disease under immune checkpoint inhibitor therapy both within and outside of clinical trials.

Schlüsselwörter

Immuntherapie - Nierenzellkarzinom - Pseudoprogress - Staging

Keywords

immunotherapy - renal cell carcinoma - staging - pseudoprogression

Publication History

Received: 22 April 2021

Accepted after revision: 22 June 2021

Article published online:
24 August 2021

• Referenzen

• 1 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
• 2 Schwartz LH, Litière S, De Vries E. et al. RECIST 1.1 - Update and clarification: From the RECIST committee. Eur J Cancer 2016; 62: 132-137
• 3 Hodi FS, Hwu WJ, Kefford R. et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab. J Clin Oncol 2016; 34: 1510-1517
• 4 Wolchok JD, Hoos A, O’Day S. et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res 2009; 15: 7412-7420
• 5 Nishino M, Giobbie-Hurder A, Gargano M. et al. Developing a common language for tumor response to immunotherapy: Immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013; 19: 3936-3943
• 6 Nishino M, Gargano M, Suda M. et al. Optimizing immune-related tumor response assessment: Does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?. 2014
• 7 Persigehl T, Lennartz S, Schwartz LH. IRECIST: How to do it. Cancer Imaging 2020; 20
• 8 George DJ, Kaelin WG. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003; 349: 419-421
• 9 Kaelin WG. The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing. J Am Soc Nephrol 2003; 14: 2703-2711
• 10 Motzer RJ, Escudier B, McDermott DF. et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373: 1803-1813
• 11 Motzer RJ, Tannir NM, McDermott DF. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018; 378: 1277-1290
• 12 Queirolo P, Spagnolo F. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. Cancer Treat Rev 2017; 59: 71-78
• 13 Soria F, Beleni AI, D’Andrea D. et al. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J Urol 2018; 36: 1703-1709
• 14 Tazdait M, Mezquita L, Lahmar J. et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 2018; 88: 38-47
• 15 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 2.0, 2020, AWMF Registernummer: 043/017OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/nierenzellkarzinom/